Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)

被引：0
|
作者：
Velez, L. [1 ,2 ]
Trevino, T. [4 ]
Kopetz, S. [3 ]
Grothey, A. [4 ]
Yaeger, R. [5 ]
Gollerkeri, A. [6 ]
Maharry, K. [6 ]
Tabernero, J. [1 ,2 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Vall dHebron Inst Oncol, Barcelona, Spain
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Tennessee, West Canc Ctr, Germantown, TN USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Pfizer Inc, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SO-21
引用
收藏
页码：S224 / S225
页数：2
相关论文
共 50 条
  • [41] Baseline characteristics of patients enrolled in the BERING CRC study: A European real-world study in BRAF V600E-mutant metastatic colorectal cancer.
    Stintzing, Sebastian
    Huebner, Gerdt
    Schroeder, Jan
    Forstbauer, Helmut
    Kisro, Jens
    Welslau, Manfred
    Mueller-Huesmann, Harald
    Buerkle, Dieter
    Krammer-Steiner, Beate
    von der Heyde, Eyck
    Reichenbach, Frank
    Arnold, Dirk
    Fritsch, Ralph M.
    Gerger, Armin
    Hegewisch-Becker, Susanna
    Vogel, Arndt
    Wagner, Anna Dorothea
    Winder, Thomas
    Koeberle, Dieter
    Prager, Gerald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15584 - E15584
  • [42] Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study
    Desai, Jayesh
    Kopetz, Scott
    Murphy, Danielle A.
    Pu, Jie
    Ciardiello, Fortunato
    Grothey, Axel
    Van Cutsem, Eric
    Wasan, Harpreet Singh
    Yaeger, Rona
    Yoshino, Takayuki
    Chantrill, Lorraine
    Tebbutt, Niall
    Strickland, Andrew
    Price, Timothy
    Karapetis, Chris
    Murphy, Felicity
    Donahue, Amber C.
    Golden, Adele
    Gollerkeri, Ashwin
    Zhu, Zhou
    Tabernero, Josep
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 89 - 89
  • [43] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Roviello, Giandomenico
    D'Angelo, Alberto
    Petrioli, Roberto
    Roviello, Franco
    Cianchi, Fabio
    Nobili, Stefania
    Mini, Enrico
    Lavacchi, Daniele
    [J]. TRANSLATIONAL ONCOLOGY, 2020, 13 (09):
  • [44] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Kopetz, S.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Desai, J.
    Yoshino, T.
    Wasan, H.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H. -T.
    Garcia-Alfonso, P.
    Pfeiffer, P.
    Orlov, S.
    Lonardi, S.
    Elez, E.
    Kim, T. -W.
    Schellens, J. H. M.
    Guo, C.
    Krishnan, A.
    Dekervel, J.
    Morris, V.
    Calvo Ferrandiz, A.
    Tarpgaard, L. S.
    Braun, M.
    Gollerkeri, A.
    Keir, C.
    Maharry, K.
    Pickard, M.
    Christy-Bittel, J.
    Anderson, L.
    Sandor, V.
    Tabernero, J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17): : 1632 - 1643
  • [45] Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
    Planchard, David
    Besse, Benjamin
    Groen, Harry J. M.
    Hashemi, Sayed M. S.
    Mazieres, Julien
    Kim, Tae Min
    Quoix, Elisabeth
    Souquet, Pierre-Jean
    Barlesi, Fabrice
    Baik, Christina
    Villaruz, Liza C.
    Kelly, Ronan J.
    Zhang, Shirong
    Tan, Monique
    Gasal, Eduard
    Santarpia, Libero
    Johnson, Bruce E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 103 - 115
  • [46] Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 199 - 202
  • [47] Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) plus binimetinib (BIM) plus cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
    Kopetz, Scott
    Grothey, Axel
    Yaeger, Rona
    Cuyle, Pieter-Jan A. R.
    Huijberts, Sanne
    Schellens, Jan H. M.
    Elez, Elena
    Fakih, Marwan
    Viladot, Clara Montagut
    Peeters, Marc
    Desai, Jayesh
    Yoshino, Takayuki
    Ciardiello, Fortunato
    Wasan, Harpreet Singh
    Maharry, Kati
    Christy-Bittel, Janna
    Gollerkeri, Ashwin
    Van Cutsem, Eric
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [48] A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
    Baik, Christina
    Cheng, Michael L.
    Dietrich, Martin
    Gray, Jhanelle E.
    Karim, Nagla A.
    [J]. ADVANCES IN THERAPY, 2024, 41 (07) : 2586 - 2605
  • [49] Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC
    von der Heyde, E.
    Buerkle, D.
    Forstbauer, H.
    Huebner, G.
    Schmidt, B.
    Schroeder, J.
    Distelrath, A.
    Wierecky, J.
    Stuebs, P.
    Kisro, J.
    Welslau, M.
    Mueller-Huesmann, H.
    Goehler, T.
    Krammer-Steiner, B.
    Schwaner, I.
    Hering-Schubert, C.
    Gerger, A.
    Greil, R.
    Jacobasch, L.
    Reichenbach, F.
    Stintzing, S.
    Prager, G.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S248 - S248
  • [50] MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH BRAF V600E-MUTANT NON-SMALL CELL LUNG CANCER TREATED WITH COMBINATION DABRAFENIB PLUS TRAMETINIB
    Wallace, Deborah
    Skotte, Emily
    Johnson, Douglas
    Horn, Leora
    [J]. ONCOLOGY NURSING FORUM, 2018, 45 (02)
12345